Ipsen Yönetim

Yönetim kriter kontrolleri 4/4

Ipsen CEO'su David Loew, Jul2020 tarihinde atandı, in görev süresi 4.33 yıldır. in toplam yıllık tazminatı € 4.36M olup, şirket hissesi ve opsiyonları dahil olmak üzere 22.6% maaş ve 77.4% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.061% ine doğrudan sahiptir ve bu hisseler € 5.44M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 5.5 yıl ve 11 yıldır.

Anahtar bilgiler

David Loew

İcra Kurulu Başkanı

€4.4m

Toplam tazminat

CEO maaş yüzdesi	22.6%
CEO görev süresi	4.3yrs
CEO sahipliği	0.06%
Yönetim ortalama görev süresi	5.5yrs
Yönetim Kurulu ortalama görev süresi	11yrs

Son yönetim güncellemeleri

We Think Shareholders May Consider Being More Generous With Ipsen S.A.'s (EPA:IPN) CEO Compensation Package

May 22

Recent updates

We Think Shareholders May Consider Being More Generous With Ipsen S.A.'s (EPA:IPN) CEO Compensation Package

May 22

Ipsen (EPA:IPN) Has Affirmed Its Dividend Of €1.20

May 08

Ipsen (EPA:IPN) Has Affirmed Its Dividend Of €1.20

Apr 20

There's Reason For Concern Over Ipsen S.A.'s (EPA:IPN) Price

Apr 13

Ipsen (EPA:IPN) Seems To Use Debt Quite Sensibly

Mar 26

Investors Still Waiting For A Pull Back In Ipsen S.A. (EPA:IPN)

Dec 30

These 4 Measures Indicate That Ipsen (EPA:IPN) Is Using Debt Reasonably Well

Dec 11

Are Investors Undervaluing Ipsen S.A. (EPA:IPN) By 31%?

Sep 28

These 4 Measures Indicate That Ipsen (EPA:IPN) Is Using Debt Reasonably Well

Sep 07

Is There An Opportunity With Ipsen S.A.'s (EPA:IPN) 34% Undervaluation?

Jun 21

Ipsen (EPA:IPN) Is Due To Pay A Dividend Of €1.20

Jun 02

Ipsen's (EPA:IPN) Dividend Will Be €1.20

May 12

Ipsen S.A. (EPA:IPN) Shares Could Be 48% Below Their Intrinsic Value Estimate

Mar 19

Ipsen (EPA:IPN) Has A Pretty Healthy Balance Sheet

Mar 01

Ipsen (EPA:IPN) Ticks All The Boxes When It Comes To Earnings Growth

Jan 19

Is There An Opportunity With Ipsen S.A.'s (EPA:IPN) 46% Undervaluation?

Dec 08

We Think Ipsen (EPA:IPN) Can Manage Its Debt With Ease

Nov 02

Does Ipsen (EPA:IPN) Deserve A Spot On Your Watchlist?

Oct 14

Does Ipsen (EPA:IPN) Have A Healthy Balance Sheet?

Aug 01

Here's Why We Think Ipsen (EPA:IPN) Might Deserve Your Attention Today

Jul 10

Ipsen (EPA:IPN) Will Pay A Larger Dividend Than Last Year At €1.20

May 26

CEO Tazminat Analizi

David Loew'un ücretlendirmesi Ipsen'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	€664m
Mar 31 2024	n/a	n/a	€641m
Dec 31 2023	€4m	€988k	€617m
Jun 30 2023	n/a	n/a	€406m
Mar 31 2023	n/a	n/a	€500m
Dec 31 2022	€4m	€950k	€593m
Sep 30 2022	n/a	n/a	€656m
Jun 30 2022	n/a	n/a	€719m
Mar 31 2022	n/a	n/a	€675m
Dec 31 2021	€5m	€950k	€631m
Sep 30 2021	n/a	n/a	€626m
Jun 30 2021	n/a	n/a	€622m
Mar 31 2021	n/a	n/a	€585m
Dec 31 2020	€5m	€475k	€548m

Tazminat ve Piyasa: David 'ın toplam tazminatı ($USD 4.57M ) French pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 3.98M ).

Tazminat ve Kazançlar: David 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

David Loew (57 yo)

4.3yrs

Görev süresi

€4,361,753

Tazminat

Mr. David Loew has been the Chief Executive Officer & MD of Ipsen S.A. since July 1, 2020, and serves as its Director since May 28, 2020. Mr. Loew served as an Executive Vice President of Sanofi Pasteur at...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
David Loew	MD, CEO & Director	4.3yrs	€4.36m	0.061% € 5.4m
Aymeric Le Chatelier	Executive VP & CFO	10yrs	€1.02m	Veri yok
Aidan Murphy	Executive VP and Head of Technical Operations	6.8yrs	Veri yok	Veri yok
Craig Marks	Vice-President of Investor Relations	no data	Veri yok	Veri yok
Francois Garnier	Executive VP of Legal Affairs	9.9yrs	Veri yok	Veri yok
Regis Mulot	Executive VP & Chief Human Resources Officer	6.7yrs	Veri yok	Veri yok
Dominique Bery	Head of Nordics & Baltics	7.6yrs	Veri yok	Veri yok
Bartosz Bednarz	Executive VP and Head of Global Product & Portfolio Strategy	4.2yrs	Veri yok	Veri yok
Philippe Lopes-Fernandes	Executive VP & Chief Business Officer	4.1yrs	Veri yok	Veri yok
James Levine	President of Fondation Ipsen	no data	Veri yok	Veri yok
Mari Scheiffele	Executive VP & President of International	3yrs	Veri yok	Veri yok
Catherine Abi-Habib	Executive VP and Head of Strategy & Transformation	2.7yrs	Veri yok	Veri yok

5.5yrs

Ortalama Görev Süresi

57.5yo

Ortalama Yaş

Deneyimli Yönetim: IPN 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.5 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
David Loew	MD, CEO & Director	4.5yrs	€4.36m	0.061% € 5.4m
Marc M. de Garidel	Non-Executive Chairman	14yrs	€600.00k	0.17% € 14.9m
Margaret Liu	Independent Director	7.4yrs	€130.00k	0.00084% € 74.2k
Michèle Ollier	Director	9.5yrs	€65.00k	0.00061% € 53.9k
Karen Witts	Independent Director	2.8yrs	€115.00k	0.00061% € 53.9k
Antoine Flochel	Vice Chairman	19.3yrs	€165.00k	0.0037% € 322.2k
Henri Beaufour	Director	19.3yrs	€36.00k	0% € 0
Anne Beaufour	Director	19.3yrs	€45.00k	26.54% € 2.3b
Carol Xueref	Director	12.4yrs	€115.00k	0.00061% € 53.9k
Philippe Bonhomme	Director	12.8yrs	€95.00k	Veri yok
Piet Wigerinck	Independent Director	6.5yrs	€78.00k	0.00083% € 73.3k
Laetitia Ducroquet	Employees Representative Director	4yrs	Veri yok	0.0010% € 89.2k

11.0yrs

Ortalama Görev Süresi

60.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: IPN 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 11 yıldır).

Ipsen Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

We Think Shareholders May Consider Being More Generous With Ipsen S.A.'s (EPA:IPN) CEO Compensation Package

Ipsen Announces Executive Changes

Recent updates

Ipsen S.A. to Report Fiscal Year 2024 Results on Feb 13, 2025

What Ipsen S.A.'s (EPA:IPN) P/E Is Not Telling You

Ipsen Provides Update on CONTACT-02 Phase III Trial in Metastatic Castration-Resistant Prostate Cancer Following Final Overall Survival Analysis

These 4 Measures Indicate That Ipsen (EPA:IPN) Is Using Debt Reasonably Well

Ipsen Receives CHMPPositive Opinions for Iqirvo® (Elafibranor) in Primary Biliary Cholangitis and Kayfanda® (Odevixibat) in Alagille Syndrome, Two Rare Cholestatic Liver Diseases

First half 2024 earnings: EPS and revenues miss analyst expectations

Ipsen S.A. Upgrades Earnings Guidance for the Full Year 2024

An Intrinsic Calculation For Ipsen S.A. (EPA:IPN) Suggests It's 42% Undervalued

Genfit S.A. Announces the Successful Corporate Milestone with U.S. FDA Accelerated Approval of Ipsen's Iqirvo for Primary Biliary Cholangitis

Ipsen S.A. Approves Dividend, Payable on 3 June 2024

Ipsen (EPA:IPN) Has Announced A Dividend Of €1.20

Upcoming dividend of €1.20 per share

We Think Shareholders May Consider Being More Generous With Ipsen S.A.'s (EPA:IPN) CEO Compensation Package

Ipsen (EPA:IPN) Has Affirmed Its Dividend Of €1.20

Ipsen Announces Executive Changes

Ipsen (EPA:IPN) Has Affirmed Its Dividend Of €1.20

Dividend of €1.20 announced

There's Reason For Concern Over Ipsen S.A.'s (EPA:IPN) Price

Ipsen (EPA:IPN) Seems To Use Debt Quite Sensibly

Ipsen’s Onivyde Regimen, Potential New Standard-Of-Care First-Line Therapy in Metastatic Pancreatic Adenocarcinoma, Approved by FDA

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Ipsen Announces Latest Phase III Trial Data Investigating Cabometyx®? in Combination with Immunotherapy to Be Present at ASCO Gu 2024

Investors Still Waiting For A Pull Back In Ipsen S.A. (EPA:IPN)

These 4 Measures Indicate That Ipsen (EPA:IPN) Is Using Debt Reasonably Well

Ipsen Confirms U.S. FDA Grants Priority Review for New Drug Application for Elafibranor for the Treatment of Rare, Cholestatic Liver Disease, PBC

Ipsen and GENFIT Announces Full Results from the Pivotal Phase III ELATIVE Trial

Ipsen S.A. to Report Q4, 2023 Results on Feb 08, 2024

Ipsen S.A. to Report First Half, 2024 Results on Jul 24, 2024

Are Investors Undervaluing Ipsen S.A. (EPA:IPN) By 31%?

These 4 Measures Indicate That Ipsen (EPA:IPN) Is Using Debt Reasonably Well

IRLAB Therapeutics AB Announces Further Information on Results from Mesdopetam’s Clinical Phase IIb Study in Parkinson’s Disease Levodopa-Induced Dyskinesias and Phase III Preparatory Phase I Studies Performed by Ipsen

First half 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Profit margin trend

Ipsen Provides Update on E.U. Marketing Authorization Application for Bylvay for Cholestatic Pruritus in Patients with Alagille Syndrome

Ipsen Announces European Commission Decision on Palovarotene for the Treatment of FOP

Ipsen and GENFIT Announces Positive Results from Phase III ELATIVE Trial of Elafibranor in Patients with Primary Biliary Cholangitis, A Rare Cholestatic Liver Disease

Is There An Opportunity With Ipsen S.A.'s (EPA:IPN) 34% Undervaluation?

Ipsen Announces U.S. FDA Submission Acceptance of Its Supplemental New Drug Application for Onivyde Regimen in First-Line Metastatic Pancreatic Ductal Adenocarcinoma

Ipsen Announces U.S. FDA Approves Bylvay® for Patients Living with Cholestatic Pruritus Due to Alagille Syndrome

Ipsen to Present New Data

Ipsen (EPA:IPN) Is Due To Pay A Dividend Of €1.20

Ipsen S.A. Approves Dividend, Payable on 6 June 2023

Upcoming dividend of €1.20 per share at 1.1% yield

Ipsen's (EPA:IPN) Dividend Will Be €1.20

Ipsen S.A. Proposes Final Dividend for the Financial Year 2022, Payable on June 6, 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

Ipsen S.A. (EPA:IPN) Shares Could Be 48% Below Their Intrinsic Value Estimate

Ipsen (EPA:IPN) Has A Pretty Healthy Balance Sheet

Full year 2022 earnings: EPS and revenues miss analyst expectations

Ipsen S.A. Provides Earnings Guidance for the Full Year 2023

Ipsen Receives CHMP Negative Opinion for Palovarotene as a Treatment for Fibrodysplasia Ossificans Progressiva in E.U

Ipsen Presents Phase III NAPOLI 3 Trial of Onivyde(R) Regimen Demonstrating Positive Survival Results in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma At Asco GI

Ipsen (EPA:IPN) Ticks All The Boxes When It Comes To Earnings Growth

Ipsen S.A. (ENXTPA:IPN) entered into a definitive merger agreement to acquire Albireo Pharma, Inc. (NasdaqCM:ALBO) for approximately $870 million.

Ipsen S.A. Provides Update on Phase III CONTACT-01 Trial Evaluating Cabozantinib

Is There An Opportunity With Ipsen S.A.'s (EPA:IPN) 46% Undervaluation?

Ipsen Announces Onivyde® Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

We Think Ipsen (EPA:IPN) Can Manage Its Debt With Ease

Ipsen S.A. Provides Earnings Guidance for the Financial Year 2023

Ipsen S.A. to Report Fiscal Year 2022 Results on Feb 09, 2023

Ipsen S.A. to Report Q2, 2023 Results on Jul 27, 2023

Ipsen S.A. to Report Q3, 2022 Results on Oct 26, 2022

Does Ipsen (EPA:IPN) Deserve A Spot On Your Watchlist?

Ipsen Announces Results from Phase III RESILIENT Trial Evaluating Onivyde in Second-Line Monotherapy for Small Cell Lung Cancer

Does Ipsen (EPA:IPN) Have A Healthy Balance Sheet?

First half 2022 earnings released

Ipsen S.A. Upgrades Earnings Guidance for the Full Year 2022

Here's Why We Think Ipsen (EPA:IPN) Might Deserve Your Attention Today

Ipsen Announces U.S. FDA Priority Review for Palovarotene New Drug Application in Patients with Fibrodysplasia Ossificans Progressiva Following Resubmission

Ipsen Announces at ASCO 2022 New Cabometyx Data Show Encouraging Results in Monotherapy and in Combination Across Different Tumor Types

Ipsen (EPA:IPN) Will Pay A Larger Dividend Than Last Year At €1.20

Ipsen S.A. Approves Dividend, Payable on 2 June 2022

Ipsen S.A. Approves Dividend, Payable on 2 June 2022